Pursuant to the provision of Regulation 30 read with Regulation 33 of SEBI (LODR), Regulations, 2015 it is hereby informed that the Board of Directors in it''s meeting held on 25.12.2025 ....
Awaiting price reaction for this filing.
Nutraplus India Ltd (BSE: 524764), an API and intermediate manufacturer, announced its unaudited standalone financial results for Q2 and H1 FY26 (ended September 30, 2025), approved by the Board on October 25, 2025. Revenue from operations collapsed to just Rs 0.67 lakh in Q2 FY26 (vs Rs 1.17 lakh in Q2 FY25) and Rs 0.98 lakh for H1 FY26 (vs Rs 3.41 lakh in H1 FY25), a steep ~71% decline for the half-year. The statutory auditor, Raman S. Shah & Associates, issued a Qualified Limited Review Report, flagging non-compliance with listing requirements and significant delays in providing financial data. An Emphasis of Matter was raised noting that the company lost all its property, plant and equipment under the SARFAESI Act (declared NPA in FY 2019-20), with bank auction procedures delayed due to COVID-19.
This is a deeply distressed filing for shareholders: the company has a negative net worth of Rs (571.52) lakh, negligible operations, and has lost all its fixed assets to banks under SARFAESI. The qualified audit opinion and going-concern-style disclosures signal severe financial stress, with very high risk to equity holders and likely continued non-compliance concerns for the stock.